Navigation Links
Alfacell Announces Receipt of NASDAQ Panel Decision
Date:1/5/2009

SOMERSET, N.J., Jan. 5 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it received notification on January 2, 2009 that the NASDAQ Listing Qualifications Panel has determined to delist the Company's securities from The NASDAQ Stock Market, effective with the open of business on Tuesday, January 6, 2009. The delisting is the result of the Company's non-compliance with the $35 million market value of listed securities requirement and its alternatives for continued listing on The NASDAQ Capital Market.

The Company has been advised that its securities are immediately eligible for quotation in the Pink Sheets, an electronic quotation service for securities traded over-the-counter, effective with the open of business on January 6, 2009. The Company's shares will continue to trade under the symbol ACEL. The Company's common stock may, in the future, also be quoted on the Over-the-Counter Bulletin Board (the "OTCBB"), an electronic quotation service maintained by the Financial Industry Regulatory Authority (or FINRA), provided that a market maker in the Company's common stock files the appropriate application with, and such application is cleared by, FINRA. The Company anticipates disclosing further trading venue information for its common stock once such information becomes available.

The Company has the right to request that the NASDAQ Listing and Hearing Review Panel review this decision and the Company may pursue this right. If the Company pursues this right of review, the decision to delist the Company's securities from The NASDAQ Stock Market will not be stayed while such review is pending.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) thro
'/>"/>

SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Alfacell Announces Management Update
2. Alfacell Reports Financial Results for First Quarter of Fiscal 2009
3. Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast
4. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
5. Go Ask Alice ... Nationally Recognized Life Coach & Psychotherapist, Alice Donavin, LCSW Announces the Implementation of Office/House Calls to her Newly Launched Philadelphia Practice
6. Mobile Massage Team Announces Eleven New Therapist Members in the Northeast U.S. Region
7. Misonix Announces New HIFU Distribution Agreement for Italy
8. Four Rivers Software Systems Announces Integration with ePartsFinder from PartsSource
9. Summa Health Network Announces Contract with MDdatacor to Support Multi-Insurer Health Care Quality Initiative; Initiative to Use Clinical Data to Supplement Claims Data and Enhance Outcomes
10. Dialysis Corporation of America Announces Acquisition of Maryland Dialysis Center
11. SXC Health Solutions announces contract with PharMerica

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...d other healthcare professionals specialising in s...t advice to guide them through the complex clinica...emic. , The paper, published online by the Ame... to stay alert to the significant concerns that sw...bly even bird flu (H5N1), to develop into a strain...
(Date:12/3/2009)...cted volunteers from virus linked to cervical canc...) -- The human papillomavirus (HPV) vaccine Cervar...ix years, new research has found. , The vaccine...PV-18) most commonly associated with cervical canc...d 15 to 25, with a normal cervical profile and no ...
(Date:12/3/2009)...ive users also feel depressed or anxious when not ...ews) -- A survey of Chinese adolescents found that...as likely to harm themselves as other teens. ,...re living in the Chinese city of Guangzhou in Guan...y had harmed themselves in some way within the pre...
(Date:12/3/2009)... The Arthritis Foundation bestowed its...cipients during its national meeting in Atlanta. ... -- The Arthritis Foundation bestowed its highest ...during its national meeting on Nov. 20 in Atlanta....ding Award for Distinguished Service ,The Arthriti...
(Date:12/3/2009)... A quick and easy way to keep a notebo...Pop up menu’s and one touch exporting keeps ...eat tool for the busy medical provider. , ...rgery , a new iPhone application for surgery, can ...medical students, and PA’s. Just about anyo...
Breaking Medicine News(10 mins):Health News:Transplant infectious disease experts provide pandemic guidance 2Health News:Transplant infectious disease experts provide pandemic guidance 3Health News:Cervarix Proves Effective Against HPV for Over 6 Years 2Health News:Teen Internet Addicts More Likely to Self-Harm: Study 2Health News:Arthritis Foundation Bestows Highest National Awards 2Health News:Arthritis Foundation Bestows Highest National Awards 3Health News:Arthritis Foundation Bestows Highest National Awards 4
...ren who are highly sensitive to allergies in the f...eveloping asthma. // Sabina Illi and colleagu...Germany, had probed and studied the outcome of exp...eir findings in the latest issue of the medical jo...
... Manchester say that a commonly used HIV drug may ...ir, the HIV drug, //could be used in prevention of...ncer cream. Dr Ian Hampson and his colleague.... The preliminary results of the study are d...
... to an outbreak of mosquito-borne encephalitis B i...deaths are in addition to the 26 people already ki...ce around 437 people have been infected with the d...xplain why there was a sudden increase in the numb...
... in Delhi who had gone on mass leave to protest ca...//for the next three months with the reservation b...mittee. "As the parliament has referred the ...the winter session and till that time we will not ...
...u of Statistics (ABS) found that the number of wom...st decade. In the new figures released by// ABS, ...t at a faster rate. About two million Austr...number of women drinking at high-risk level had do...
... Pennsylvania have disclosed that a specific varie...o bone, muscle, neurons or other// types of tissue...onment. The researchers found that mesench...to different types of tissue. The researchers were...
Other Medicine News:Health News:Babies Prone To Allergies More likely To Be Asthmatic 2Health News:Medicos Suspends Anti-quota Stir 2Health News:Adult stem cells are sensitive to responses from the environment 2
(Date:12/3/2009)...ire/ -- Apnex Medical, Inc., a private medical dev...ond round of private equity financing totaling $14...nical study and develop a second generation of its...eat obstructive sleep apnea (OSA). ,, Participa...w Enterprise Associates (NEA), Polaris Venture Par...
(Date:12/3/2009)...c. 3 Omnicell, Inc ., (...ystem solutions to acute healthcare facilities, to...CHS), the largest healthcare system in the Carolin...he nation, has chosen Omnicell OmniRx® automa...mline management of medications in its hospitals. ...
(Date:12/3/2009)...09 Raytheon BBN Technologies, a wh... RTN ), has licensed its patented, award-winning s...FILM Corp. ,, FUJIFILM intends to interface th...ombined with SDM technology, the Aspire HD digital... 3-D viewing. FUJIFILM will display the Raytheon B...
Breaking Medicine Technology:Apnex Medical, Inc. Raises Additional $14 Million 2Apnex Medical, Inc. Raises Additional $14 Million 3Omnicell Selected by Nation's Third Largest Public Healthcare System for Medication Management Systems 2Omnicell Selected by Nation's Third Largest Public Healthcare System for Medication Management Systems 3Omnicell Selected by Nation's Third Largest Public Healthcare System for Medication Management Systems 4Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation 2Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation 3Health Robotics CytoCare 28TM 29 Global Expansion Continues With Grifols International in Latin America 5212 1Health Robotics CytoCare 28TM 29 Global Expansion Continues With Grifols International in Latin America 5212 2Health Robotics CytoCare 28TM 29 Global Expansion Continues With Grifols International in Latin America 5212 3DNA test could be key to targeting treatments for head and neck cancer 58856 1DNA test could be key to targeting treatments for head and neck cancer 58856 2University of Washington receives 2425 million to create Northwest Genomics Center 10256 1University of Washington receives 2425 million to create Northwest Genomics Center 10256 2University of Washington receives 2425 million to create Northwest Genomics Center 10256 3University of Washington receives 2425 million to create Northwest Genomics Center 10256 4
...lp Educate on Good,Diabetes Management and How to ...SEATTLE, April 10, 2007 /PRNewswire/ -- A first-of...t of type 2 diabetes,complications shows that an e...ith type 2 diabetes have at least one of the other...the disease, and,that these health problems are ta...
...ll/ -- ImClone,Systems Incorporated and Bristol-My...I study of ERBITUX(R) (Cetuximab) plus,gemcitabine...d,unresectable or metastatic pancreatic cancer did...l survival. , Conducted by the Southwest Oncology ... the National Cancer Institute, the,open-label, ra...
Other Medicine Technology:First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9
FirstChoice Drainable Pouches, Convex
FirstChoice Drainable Pouch, FlexWear, Cut-to-Fit
FirstChoice Drainable Kit
FirstChoice Closed Pouches
Medicine Products: